Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people regain weight after stopping Mounjaro — and that's not a personal failing, it's biology. Clinical trials show that when tirzepatide is discontinued, appetite and hunger signals typically return, and much of the lost weight can come back within months. That reality is worth understanding before you stop, not after. Mounjaro (tirzepatide) is a prescription-only medicine; any decision to pause, reduce or stop treatment should be made with your prescriber, not unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most persistent misconception about Mounjaro is that it works like a course of antibiotics, you finish it, you keep the result. That's not how tirzepatide works. It acts on GIP and GLP-1 receptors to suppress appetite and slow gastric emptying. While you're taking it, those signals are moderated. When treatment stops, they're not.
Data from the broader tirzepatide clinical programme, involving thousands of adults across the SURMOUNT trials, consistently show that participants who discontinued the medicine regained a substantial portion of lost weight over the following year. This isn't because the treatment failed. It reflects something the NHS tirzepatide information page states plainly: obesity is a chronic condition, and medicines that treat it work while they're taken. Framing discontinuation as a finish line leads to avoidable disappointment. Understanding it as a pause (with predictable consequences) is more useful.
If you've been wondering about what stopping Mounjaro involves more broadly, there's more detail on how to approach that conversation with your prescriber.
Tirzepatide has a half-life of roughly five days, which means it takes around three to four weeks to clear substantially from the body. During that window, people often notice a gradual return of appetite, not overnight, but incrementally. The feeling of fullness that came easily at mealtimes fades. Food noise, the background preoccupation with eating that many patients describe quietening on treatment, often comes back.
Gastric emptying, which tirzepatide slows down, returns to its previous pace. That can mean meals feel less satisfying than they did on treatment, even before hunger itself intensifies. Some people also notice bloating after stopping Mounjaro as their gut adjusts, and others report stomach discomfort in the days following their last injection, though neither is universal.
On the practical side: if you keep your pen in the fridge door as part of a weekly routine, that absence becomes a concrete reminder. Many people find that the routines built around injecting (Saturday morning, before the kettle goes on) are worth consciously replacing with something else to maintain momentum with diet and activity.
The honest answer is: it varies, and the data skews towards more rather than less. In post-discontinuation follow-up periods from the SURMOUNT programme, participants regained a meaningful share of what they'd lost within twelve months of stopping. The rate of regain tends to be fastest in the first few months, then slows. People who've built strong dietary habits and activity routines during treatment tend to fare better than those who relied entirely on appetite suppression, but few maintain full results without the medicine.
NICE's appraisal of tirzepatide (TA1026, published December 2024) notes that review of ongoing treatment considers weight response, which reflects the understanding that this is a long-term intervention. Stopping early in treatment, or after only a short period at low doses, tends to mean less weight was lost to begin with. If you stopped after a short trial, our page on stopping Mounjaro after one week covers that specific situation.
Restarting is possible, and for many people it's clinically appropriate. There's no rule that says one course means you're done. The question is whether the medicine is still suitable for you, your weight, health status and any medicines you're taking may have changed since you last had a prescription.
In practice, anyone who stops and then wants to restart will need a fresh clinical assessment. That includes a review of current weight and any new health information. Depending on how long treatment was paused, the prescriber will also advise on whether to begin again at 2.5mg or at a previously tolerated dose, getting that wrong can mean unnecessary side effects. You can read more about going back on Mounjaro after stopping on a dedicated page. For a broader picture of tirzepatide and how it works, the tirzepatide overview covers the mechanism and clinical background in detail.
If you're weighing up whether to continue, pause or try a different approach, a free consultation with our prescribers lets you talk through your situation with someone who can review your history properly. Check your eligibility and start a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.